Speaker Profile

Ph.D., VP, Head of Science, Labcorp Oncology, Labcorp

Biography
After studying in the field of cancer epigenetics, Taylor Jensen, Ph.D. joined Sequenom in 2009 and was part of the team that developed and launched the first commercially available noninvasive prenatal test based on circulating cell-free DNA (cfDNA) in the U.S. Subsequently, Dr. Jensen has been involved in numerous assay development efforts focused on the identification and detection of genetic and epigenetic changes in cfDNA for use in prenatal and cancer diagnostics. Since the acquisition of Sequenom by LabCorp in 2016, his work has been primarily focused on precision medicine assay development and product strategy in oncology with the overarching goal of utilizing innovative technologies to improve human health.


Clinical Dx Showcase:
Labcorp

Through unparalleled diagnostics and drug development capabilities, Labcorp provides insights and accelerate innovations to improve health and improve lives.

Personalized Cancer Care-The Role of Somatic and Germline NGS Testing
Cancer is a disease of the genome with aberrations derived from both somatic and germline origins; therefore, a comprehensive genetic assessment of the tumor may be optimal to guide treatment, prognosis, and future risk for a patient and their family.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6 - June 28 9.00 A.M.-4.45 P.M.,Track 6 - June 29 3.30 P.M.-3.45 P.M.,Track 6 - June 30 9.00 A.M.-1.15 P.M.


The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative